The addition of pembrolizumab to neoadjuvant chemoradiotherapy did not increase the risk of developing postoperative anastomotic leakage for ESCC: an analysis from a prospective cohort
Based on our prospective database, no significant difference of developing AL were observed between NCRT with pembrolizumab and NCRT group. We established an individualized nomograms based on mean GF dose combined with clinical indicators to predict AL in the early postoperative period.
Authors
- Wei‐Xiang Qi (ORCID: https://orcid.org/0000-0001-5484-3343)
- Huan Li (ORCID: https://orcid.org/0000-0003-3878-0973)
- Jiayi Chen (ORCID: https://orcid.org/0000-0001-6417-290X)
- Shuyan Li (ORCID: https://orcid.org/0000-0001-7028-4166)
- Shengguang Zhao (ORCID: https://orcid.org/0000-0002-4197-8887)
Institutions
- Ruijin Hospital (CN)
- Shanghai Genon Biological Products (China) (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1186/s12885-024-12774-w
- Citations
- 6
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- National Science Foundation
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China